anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

All filtered slides

Global slide inventory for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations
18 30 60

Slide collection

173,521-173,580 of 319,975

filter-aware
01
Slide 1
Background pattern consists of DNA base pairs (A, C, G, T).23andMe | Investor Presentation Deck | 63 slides · 23andMe
Pitch deck Investor relations 1 hit
02
23andMe | Investor Presentation Deck | 63 slides23andMe | Investor Presentation Deck | 63 slides · 23andMe
Pitch deck Investor relations 1 hit
03
The background contains scattered DNA base letters (A, T, C, G), suggesting a biotech or healthcare context.23andMe | Investor Presentation Deck | 63 slides · 23andMe
Pitch deck Investor relations 1 hit
04
The chart uses a gradient arrow to emphasize the scale of 12.2M participants compared to other biobanks.23andMe | Investor Presentation Deck | 63 slides · 23andMe
Pitch deck Investor relations 1 hit
05
The slide uses a split-screen layout with a quote on the left and quantitative evidence on the right.23andMe | Investor Presentation Deck | 63 slides · 23andMe
Pitch deck Investor relations 1 hit
06
Uses a list of industry-disruptor pairs to build a case for the company's thesis.23andMe | Investor Presentation Deck | 63 slides · 23andMe
Pitch deck Investor relations 1 hit
07
The slide uses a timeline format to demonstrate regulatory milestones and credibility.23andMe | Investor Presentation Deck | 63 slides · 23andMe
Pitch deck Investor relations 1 hit
08
The slide combines quantitative traction metrics with a qualitative customer story to validate the product's value proposition.23andMe | Investor Presentation Deck | 63 slides · 23andMe
Pitch deck Investor relations 1 hit
09
The slide uses a DNA-themed background with scattered A, T, C, G letters.23andMe | Investor Presentation Deck | 63 slides · 23andMe
Pitch deck Investor relations 1 hit
10
The slide uses a split-screen design with a gradient background on the left and white space on the right. The 'ACGT' letters are stylized as a logo/graphic element.23andMe | Investor Presentation Deck | 63 slides · 23andMe
Pitch deck Investor relations 1 hit
11
The slide highlights the scale of the 23andMe database and its application across three business pillars.23andMe | Investor Presentation Deck | 63 slides · 23andMe
Pitch deck Investor relations 1 hit
12
The slide uses a circular process flow to represent a self-reinforcing business model.23andMe | Investor Presentation Deck | 63 slides · 23andMe
Pitch deck Investor relations 1 hit
13
The slide showcases three core product features using mobile and web UI screenshots.23andMe | Investor Presentation Deck | 63 slides · 23andMe
Pitch deck Investor relations 1 hit
14
Uses a flow diagram to show the gap in healthcare coverage for BRCA testing.23andMe | Investor Presentation Deck | 63 slides · 23andMe
Pitch deck Investor relations 1 hit
15
The slide highlights the breadth of genetic reporting and emphasizes FDA authorizations.23andMe | Investor Presentation Deck | 63 slides · 23andMe
Pitch deck Investor relations 1 hit
16
Includes two mobile UI mockups showing personalized user results.23andMe | Investor Presentation Deck | 63 slides · 23andMe
Pitch deck Investor relations 1 hit
17
The slide highlights the value proposition of the premium subscription tier.23andMe | Investor Presentation Deck | 63 slides · 23andMe
Pitch deck Investor relations 1 hit
18
The slide features a background pattern of DNA base pairs (A, T, C, G) and a central circle with the number 3.23andMe | Investor Presentation Deck | 63 slides · 23andMe
Pitch deck Investor relations 1 hit
19
The chart highlights that health care only accounts for 10% of the risk of premature death, framing the opportunity for non-clinical interventions.23andMe | Investor Presentation Deck | 63 slides · 23andMe
Pitch deck Investor relations 1 hit
20
The slide uses a gradient color scheme for the bars. The data is sourced from a 2019 survey of 1,046 customers.23andMe | Investor Presentation Deck | 63 slides · 23andMe
Pitch deck Investor relations 1 hit
21
Uses a visual contrast between uniform yellow figures (reactive) and diverse, multi-colored figures (proactive) to illustrate the shift from one-size-fits-all to personalized care.23andMe | Investor Presentation Deck | 63 slides · 23andMe
Pitch deck Investor relations 1 hit
22
Uses a simple equation-style visual to show the merger/partnership of two entities resulting in a set of service offerings.23andMe | Investor Presentation Deck | 63 slides · 23andMe
Pitch deck Investor relations 1 hit
23
23andMe | Investor Presentation Deck | 63 slides23andMe | Investor Presentation Deck | 63 slides · 23andMe
Pitch deck Investor relations 1 hit
24
23andMe | Investor Presentation Deck | 63 slides23andMe | Investor Presentation Deck | 63 slides · 23andMe
Pitch deck Investor relations 1 hit
25
The slide uses a gradient background and visual representations of mobile app screens to illustrate the integration of genetic insights into primary care.23andMe | Investor Presentation Deck | 63 slides · 23andMe
Pitch deck Investor relations 1 hit
26
The slide features a gradient background with scattered DNA base letters (A, T, C, G) and a central circle containing the number 4.23andMe | Investor Presentation Deck | 63 slides · 23andMe
Pitch deck Investor relations 1 hit
27
The slide uses a split-screen layout with a blue background on the left for the core problem statement and a white background on the right for supporting metrics.23andMe | Investor Presentation Deck | 63 slides · 23andMe
Pitch deck Investor relations 1 hit
28
The slide uses a contrast-pair framework to highlight the competitive advantage of 23andMe over the traditional industry.23andMe | Investor Presentation Deck | 63 slides · 23andMe
Pitch deck Investor relations 1 hit
29
The slide uses a combination of a grid of metrics for general health conditions and a timeline for the COVID-19 study.23andMe | Investor Presentation Deck | 63 slides · 23andMe
Pitch deck Investor relations 1 hit
30
Includes a conceptual diagram of SNP comparison and a multi-level zoom-in Manhattan plot.23andMe | Investor Presentation Deck | 63 slides · 23andMe
Pitch deck Investor relations 1 hit
31
The slide uses Manhattan plots to show genetic association density over time and a line chart to show the cumulative growth of independent hits.23andMe | Investor Presentation Deck | 63 slides · 23andMe
Pitch deck Investor relations 1 hit
32
The slide uses a grid of small-multiple charts to show genetic association data across 12 medical categories. A specific example for NAFLD is highlighted at the bottom.23andMe | Investor Presentation Deck | 63 slides · 23andMe
Pitch deck Investor relations 1 hit
33
The slide uses a central diagram of the TSLP receptor complex connected to five regional association plots (LocusZoom-style plots).23andMe | Investor Presentation Deck | 63 slides · 23andMe
Pitch deck Investor relations 1 hit
34
The heatmap shows log(OR) values for three TSLP GWAS signals across various diseases.23andMe | Investor Presentation Deck | 63 slides · 23andMe
Pitch deck Investor relations 1 hit
35
The slide uses a funnel metaphor to show the narrowing of research targets.23andMe | Investor Presentation Deck | 63 slides · 23andMe
Pitch deck Investor relations 1 hit
36
The slide uses a timeline-style layout to show drug development stages from Discovery to Phase 2.23andMe | Investor Presentation Deck | 63 slides · 23andMe
Pitch deck Investor relations 1 hit
37
23andMe | Investor Presentation Deck | 63 slides23andMe | Investor Presentation Deck | 63 slides · 23andMe
Pitch deck Investor relations 1 hit
32
The slide uses a hierarchical pillar-and-tactic structure to map organizational goals to specific activities.Vigil Neuroscience | IPO Presentation Deck | 54 slides · Vigil Neuroscience
Pitch deck Investment bank 1 hit
33
Includes footnotes regarding clinical trial status and regulatory expectations.Vigil Neuroscience | IPO Presentation Deck | 54 slides · Vigil Neuroscience
Pitch deck Investment bank 1 hit
34
The slide uses a top-down funnel approach to narrow the market from general leukodystrophies to the specific ALSP indication.Vigil Neuroscience | IPO Presentation Deck | 54 slides · Vigil Neuroscience
Pitch deck Investment bank Beat · Market Size1 hit
35
Vigil Neuroscience | IPO Presentation Deck | 54 slidesVigil Neuroscience | IPO Presentation Deck | 54 slides · Vigil Neuroscience
Pitch deck Investment bank 1 hit
36
The slide presents a technical specification table for a drug development program.Vigil Neuroscience | IPO Presentation Deck | 54 slides · Vigil Neuroscience
Pitch deck Investment bank 1 hit
37
The chart shows dose-response curves for VG-2862 concentration vs. pSYK activation signal, comparing 'No Fab' (control) against four different Fabs.Vigil Neuroscience | IPO Presentation Deck | 54 slides · Vigil Neuroscience
Pitch deck Investment bank 1 hit
38
The slide shows four dose-response plots. The EC50 values are explicitly labeled for the three active cases.Vigil Neuroscience | IPO Presentation Deck | 54 slides · Vigil Neuroscience
Pitch deck Investment bank 1 hit
39
The data highlights the specificity of the drug candidate for brain tissue over peripheral circulation.Vigil Neuroscience | IPO Presentation Deck | 54 slides · Vigil Neuroscience
Pitch deck Investment bank 1 hit
40
The slide uses box plots to compare control vs VG-3440 across six different biological metrics.Vigil Neuroscience | IPO Presentation Deck | 54 slides · Vigil Neuroscience
Pitch deck Investment bank 1 hit
41
The slide uses checkmarks for completed milestones and empty squares for future milestones, effectively acting as a status tracker.Vigil Neuroscience | IPO Presentation Deck | 54 slides · Vigil Neuroscience
Pitch deck Investment bank 1 hit
42
Vigil Neuroscience | IPO Presentation Deck | 54 slidesVigil Neuroscience | IPO Presentation Deck | 54 slides · Vigil Neuroscience
Pitch deck Investment bank 1 hit
43
The slide uses a hub-and-spoke diagram to visualize the market opportunity for a platform technology targeting microglial function.Vigil Neuroscience | IPO Presentation Deck | 54 slides · Vigil Neuroscience
Pitch deck Investment bank 1 hit
44
Includes a Manhattan plot (GWAS) and immunohistochemistry images with quantitative analysis of microglia clustering.Vigil Neuroscience | IPO Presentation Deck | 54 slides · Vigil Neuroscience
Pitch deck Investment bank 1 hit
45
Slide contains multiple microscopy images and bar charts showing experimental results from Yuan et al (2016) and Wang et al (2020).Vigil Neuroscience | IPO Presentation Deck | 54 slides · Vigil Neuroscience
Pitch deck Investment bank 1 hit
46
The slide presents histological images and quantitative dot plots comparing Trem2 wild-type, heterozygous, and knockout mice.Vigil Neuroscience | IPO Presentation Deck | 54 slides · Vigil Neuroscience
Pitch deck Investment bank 1 hit
47
Vigil Neuroscience | IPO Presentation Deck | 54 slidesVigil Neuroscience | IPO Presentation Deck | 54 slides · Vigil Neuroscience
Pitch deck Investment bank 1 hit
48
The slide uses a linear process flow to illustrate the drug development strategy.Vigil Neuroscience | IPO Presentation Deck | 54 slides · Vigil Neuroscience
Pitch deck Investment bank 1 hit
49
The slide uses a structured matrix to justify pipeline expansion by highlighting significant unmet medical needs across three rare diseases.Vigil Neuroscience | IPO Presentation Deck | 54 slides · Vigil Neuroscience
Pitch deck Investment bank 1 hit
50
The slide uses a causal chain diagram to explain the disease progression and a biological process diagram to explain the therapeutic intervention.Vigil Neuroscience | IPO Presentation Deck | 54 slides · Vigil Neuroscience
Pitch deck Investment bank 1 hit
51
Vigil Neuroscience | IPO Presentation Deck | 54 slidesVigil Neuroscience | IPO Presentation Deck | 54 slides · Vigil Neuroscience
Pitch deck Investment bank 1 hit
52
The slide uses a checklist format to indicate progress, with the first item marked as completed.Vigil Neuroscience | IPO Presentation Deck | 54 slides · Vigil Neuroscience
Pitch deck Investment bank 1 hit
53
The slide uses a Venn-like overlapping circle layout to connect scientific rationale, team capability, and mission.Vigil Neuroscience | IPO Presentation Deck | 54 slides · Vigil Neuroscience
Pitch deck Investment bank 1 hit
54
Vigil Neuroscience | IPO Presentation Deck | 54 slidesVigil Neuroscience | IPO Presentation Deck | 54 slides · Vigil Neuroscience
Pitch deck Investment bank 1 hit